SK Biopharmaceuticals
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player 2024-11-19 08:00
SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada 2024-03-12 08:00
SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit 2023-10-31 08:00
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023-10-13 09:00
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference 2023-09-27 08:30
SK Biopharmaceuticals Assembles 'Board of Prominent Experts' to Boost Growth, Innovation 2023-08-03 07:30
SK Biopharmaceuticals Makes Big Bets to be 'Big Biotech' 2023-07-18 09:00
SK Biopharmaceuticals Wins Red Dot Design Award for Wearable Devices 2023-04-11 08:00
SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night' 2023-01-10 07:00
SK Biopharmaceuticals CEO Donghoon Lee Buys 3,000 Shares of Company Stock 2023-01-06 09:10
SK Biopharmaceuticals Unveils Vision for Digital Healthcare 2022-12-14 10:00
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France 2022-12-09 06:30
SK Biopharmaceuticals Wins Export Award for Cenobamate 2022-12-06 08:00
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device at AES 2022 2022-12-05 08:00
SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO 2022-12-01 09:30
SK Biopharmaceuticals Named CES 2023 Innovation Awards Honoree 2022-11-17 07:09
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969 2022-11-14 08:00
1